Author

Catherine Reinert

Institutions: University of Colorado Health, University of Colorado Cancer Center

Observed institutions: Denver Health Medical Center, University of Colorado Health, University of Colorado Cancer Center, University of Colorado Anschutz

OpenAlex ID: A5113036949

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

2025 · Taylor R. Brooks, Emily C. Zabor, et al. · Blood · 40

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

2024 · Taylor R. Brooks, Emily C. Zabor, et al. · Blood · 15

Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study

2026 · John Sharp, Paolo Strati, et al. · Blood Advances · 6

Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers

2024 · John Sharp, Paolo Strati, et al. · Blood · 3

Palliative medicine referral trends by demographics for patients with stage IV cancer at an urban safety net hospital.

2023 · Sandhya Sharma, Catherine Reinert, et al. · Journal of Clinical Oncology · 3

Outcomes following disease progression after epcoritamab or glofitamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective cohort study

2025 · Taylor Brooks, Agrima Mian, et al. · Blood · 1

Risk factors for cytokine release syndrome and neurotoxicity in patients receiving epcoritamab or glofitamab for large B cell lymphoma: A multi-center, retrospective, real world analysis.

2025 · XI Yang, Yasmin Karimi, et al. · Blood · 1

Quality improvement initiative to increase bone mineral density screening with DEXA scans among patients receiving aromatase inhibitors or androgen deprivation therapy at an urban safety-net hospital.

2023 · Sandhya Sharma, Catherine Reinert, et al. · JCO Oncology Practice · 1

Real World Outcomes and Predictive Factors of Pirtobrutinib in Mantle Cell Lymphoma After Failure of Covalent Bruton Tyrosine Kinase Inhibitors

2026 · Tycel Phillips, Paolo Lopedote, et al. · Research Square

Evaluation of outcomes and toxicities of loncastuximab tesirine (Lonca) in relapse/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Real-world data analysis (RWDA) from 10 US academic centers

2025 · Alex Niu, Alan Hutson, et al. · Blood

Works count: 10

Citation count: 70

H-index: 3

I10-index: 2